Comparing Frovatriptan and Almotriptan for Migraine Treatment
Author Information
Author(s): Bartolini Marco, Giamberardino Maria Adele, Lisotto Carlo, Martelletti Paolo, Moscato Davide, Panascia Biagio, Savi Lidia, Pini Luigi Alberto, Sances Grazia, Santoro Patrizia, Zanchin Giorgio, Omboni Stefano, Ferrari Michel D., Brighina Filippo, Fierro Brigida
Primary Institution: G. D’Annunzio University, Chieti, Italy
Hypothesis
Is one treatment more effective than the other for acute migraine relief?
Conclusion
Frovatriptan and almotriptan have similar short-term efficacy for treating migraines, but frovatriptan shows a lower risk of recurrence over the long term.
Supporting Evidence
- 114 patients expressed a preference for one of the treatments.
- The average preference score was similar for both medications.
- Frovatriptan showed a lower rate of recurrent episodes compared to almotriptan.
Takeaway
This study looked at two migraine medications to see which one works better. Both are good, but one might help keep headaches away longer.
Methodology
The study was a multicenter, randomized, double-blind, cross-over design involving 133 patients who were treated with either frovatriptan or almotriptan.
Potential Biases
Potential bias due to patient preference and self-reported outcomes.
Limitations
Some patients withdrew from the study, and the sample size may limit the generalizability of the findings.
Participant Demographics
Most participants were female (84%), aged 18-65, with a history of migraine.
Statistical Information
P-Value
NS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website